logo
Plus   Neg
Share
Email

Merck: CHMP Supports KEYTRUDA Plus Inlyta To Treat Advanced Renal Cell Carcinoma

Merck (MRK) said CHMP, the Committee of the European Medicines Agency, has recommended approval of KEYTRUDA plus Inlyta combination for the first-line treatment of patients with advanced renal cell carcinoma. The final decision by the European Commission is anticipated in the third quarter of 2019.

The CHMP recommendation is based on the results from the Phase 3 KEYNOTE-426 trial, which showed significant improvements in overall survival, progression-free survival and objective response rate for KEYTRUDA in combination with axitinib compared to sunitinib.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Commerzbank AG (CRZBY.PK) said Friday that it plans to cut 4,300 jobs, as part of its strategy. It also plans to sell its majority stake in mbank S.A. It is considering making a purchase offer to Comdirect's outstanding shareholders. Walmart, which has said its goal is to become America's neighborhood health destination, is hosting a free wellness event in its stores across the country on Saturday, September 21. The "Walmart Wellness Day" event will held be from 10 a.m. to 2 p.m. at more than 4,600 Walmart stores with pharmacies. Customers can visit these stores to get free health screenings and low-cost flu shots. Exploding Kittens Inc. recalled 11,235 units of safety goggles sold with Throw Throw Burrito Extreme Going Pro Edition Dodgeball Card Game sets for concerns of laceration hazard if shattered. These include 735 units sold in Canada, a statement published by the U.S. Consumer Product Safety Commission said.
Follow RTT
>